(Q34750126)

4 August 2017

1 reference

title

Quality of life and cost of multiple sclerosis (English)

1 reference

4 August 2017

0 references

1 reference

Carolin Miltenburger

1

1 reference

4 August 2017

Gisela Kobelt

series ordinal

2

1 reference

4 August 2017

publication date

1 July 2002

1 reference

Clinical Neurology and Neurosurgery

4 August 2017

published in

1 reference

4 August 2017

volume

104

1 reference

4 August 2017

issue

3

1 reference

4 August 2017

page(s)

272-275

1 reference

How many people in the world have multiple sclerosis?

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900051-3

7 January 2021

[Projection of the number of multiple sclerosis patients in Germany]

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900051-3

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900051-3

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900051-3

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900051-3

7 January 2021

Interferon-beta in multiple sclerosis. Can we control its costs?

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900051-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900051-3

7 January 2021

The economic cost of multiple sclerosis in Sweden in 1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900051-3

7 January 2021

Impairment, disability, and handicap in multiple sclerosis. A cross-sectional study in an incident cohort in Møre and Romsdal County, Norway

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900051-3

7 January 2021

Burden of illness of multiple sclerosis: Part I: Cost of illness. The Canadian Burden of Illness Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900051-3

7 January 2021

Economic Evaluation of Multiple Sclerosis in the UK, Germany and France

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900051-3

7 January 2021

A comprehensive assessment of the cost of multiple sclerosis in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900051-3

7 January 2021

Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900051-3

7 January 2021

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900051-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900051-3

7 January 2021

Validation of the functional assessment of multiple sclerosis quality of life instrument

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900051-3

7 January 2021

Impact of aerobic training on fitness and quality of life in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900051-3

7 January 2021

The Sickness Impact Profile: Development and Final Revision of a Health Status Measure

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900051-3

7 January 2021

Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900051-3

7 January 2021

10.1016/S0303-8467(02)00051-3

Identifiers

DOI

1 reference

4 August 2017

1 reference